Analysis Of The intrahepatic ductular reaction and progenitor cell responses in hepatitis C virus recurrence Post-Liver transplantation by Prakoso, E. et al.
 
 
Analysis Of The Intrahepatic Ductular Reaction And Progenitor Cell Responses In Hepatitis 





, Janina E.E. Tirnitz-Parker
4,5*







, Eng K. Gan
5,8
, Grant A. Ramm
9
, James G. Kench
3,10
, David G. Bowen
1,2,3
, John K. Olynyk
4, 
8,11
, Geoffrey W. McCaughan
1,2,3






Centenary Institute of Cancer Medicine and Cell Biology, Sydney, New South Wales (NSW), 
Australia  
2
A.W. Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital (RPAH), Sydney, 
NSW, Australia 
3
University of Sydney, Sydney, NSW, Australia 
4
School of Biomedical Sciences, CHIRI Biosciences Research Precinct, Curtin University, Bentley, 
Western Australia (WA), Australia 
5
School of Medicine and Pharmacology, University of Western Australia, Nedlands, WA, Australia 
6
Centre for Liver Disease Research, School of Medicine, University of Queensland, Queensland 
(QLD), Australia 
7
Liver Transplant Program, Transplantation Institute, Loma Linda University Medical Center, 
Loma Linda, California, USA 
8
Department of Gastroenterology, Fremantle Hospital, Fremantle, WA, Australia 
9
Liver Fibrosis Group, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia 
10
Department of Tissue Pathology and Diagnostic Oncology, RPAH, Sydney, NSW, Australia 
11
Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, WA, Australia 
*These authors contributed equally to this study 
 
Running Title : 
Ductular reaction in recurrent HCV post-transplant 
 
Keywords : 
Hepatic progenitor cell, liver fibrosis, liver inflammation, liver injury, hepatocyte replicative arrest 
This article has been accepted for publication and undergone full peer review but has not been
through the copyediting, typesetting, pagination and proofreading process which may lead to
differences between this version and the Version of Record. Please cite this article as an




Abbreviation list: α-SMA, alpha-smooth muscle actin; ALP, alkaline phosphatase; ALT, alanine 
aminotransaminase; AST, aspartate aminotransaminase; DAPI, 4',6-diamidino-2-phenylindole; DR, 
ductular reaction; F, fibrosis stage; GGT, gamma-glutamyl transferase; G, genotype; HCV, hepatitis 
C virus; HPC, hepatic progenitor cell; HRP, horseradish peroxidase; HSC, hepatic stellate cell; K, 
keratin; LT, liver transplantation; SE, standard error. 
 
Conflicts of interest: 




Centenary Institute of Cancer Medicine and Cell Biology, Sydney, NSW 2050, Australia  
n.shackel@centenary.usyd.edu.au 
Tel: +612 95656286; Fax: +612 95656101  
Page 2 of 37






Background: Fibrosis in liver with hepatitis C virus (HCV) recurrence post-liver transplantation 
(LT) can be rapidly progressive and the mechanisms underlying this process are poorly understood.  
In liver with HCV infection in the non-LT setting, there is a significant relationship between the 
development of structures known as the ductular reaction (DR), hepatic progenitor cells (HPCs) and 
fibrosis. In this study, we have characterized the DR, HPCs and fibrosis associated with HCV 
recurrence post-LT.  
 
Methods: Immunohistochemistry and confocal microscopy were used to characterize the DR, HPC 
and fibrosis in liver biopsy specimens. Key findings were confirmed in a separate independent 
cohort. 
 
Results: The initial characterization cohort had 194 biopsy samples from 105 individuals with HCV 
recurrence post-LT. The immunophenotype, morphology and location of the DR was consistent 
with an HPC origin. The DR correlated with intrahepatic fibrosis (rs=0.529, p<0.001) and numbers 
of activated hepatic stellate cells (HSCs, rs=0.446, p<0.001). There was an early occurrence of 
hepatocyte replicative arrest and increased hepatocyte proliferation that correlated with the DR 
(rs=0.295, p<0.001). Replicative arrest preceded hepatocyte proliferation in early stage injury. 
Hepatocyte proliferation decreased with advanced fibrosis, in contrast the extent of the DR and 
numbers of activated HSCs continued to increase. In the second cohort of 37 individuals, the DR 
and numbers of HPCs similarly correlated with fibrosis and inflammation post-LT. 
 
Conclusions: This is the first characterization of the DR in HCV-associated liver injury post-LT. 
There was a significant correlation between the DR and the development of progressive fibrosis in 
HCV recurrence. These results suggest a pivotal role for both the DR and HPC responses in the 
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Currently hepatitis C virus (HCV)-associated cirrhosis is the commonest indication for liver 
transplantation (LT) worldwide.
1-3
 It is now established that recurrent HCV infection is associated 
with a 23% increased mortality rate and a 30% increased allograft failure rate compared to 
transplant performed for non-HCV related indications.
4
 HCV re-infection of the allograft is 
inevitable, leading to allograft hepatitis in 50-80% at 2 years.
5-10
 HCV-related fibrosis is accelerated 
in the post-LT immunocompromised patient compared to the pre-LT patient,
11
 with cirrhosis 
observed in 21% of patients at 5 years.
6
 It has been reported that the median duration from 
transplantation to HCV-related allograft cirrhosis is approximately 9-12 years with a 42% risk for 




The pathogenesis of liver injury in chronic HCV infection prior to LT has been extensively 
investigated. Following HCV infection and resultant chronic intrahepatic inflammation, hepatocytes 
are continuously damaged and undergo replicative arrest, which activates an intrahepatic stem cell-
like compartment of hepatic progenitor cells (HPCs).
13-15
 Dependent on the injury, HPCs either 
proliferate as ductular structures,
16
 or as strings of parenchymal cells, which can appear as single 
cells in two-dimensional sections.
17
 They migrate from periportal to pericentral areas to mediate 
liver regeneration.
18, 19
 As the proliferation of HPCs generally is of a ductular phenotype, in human 
liver they are referred to as the “ductular reaction” (DR).
13, 20
 However, HPCs are not confined to 
the DR and non-ductular strings of HPCs, which sometimes appear as single cells, are frequently 
observed in adjacent areas.
17
 HPCs and the DR are spatially and temporarily associated with 
fibrosis-driving hepatic stellate cells (HSCs) and a close relationship between the DR, HPCs, 
inflammation and fibrosis has been repeatedly reported in liver with HCV infection.
13-15, 21
 
Importantly, it has been established in the pre-LT setting that HPC numbers and the amplitude of 
the DR directly correlate with the severity of fibrosis.
13-15, 21
 Interactions between the DR, HPCs 
and HSCs are mediated via a number of autocrine and paracrine pathways, which are poorly 




A recent study outlined a role for HPC proliferation in HCV-associated fibrosis progression post-
LT.
30
 This study reported an increased expression of keratin (K)-19, an HPC and biliary epithelial 
marker, in individuals with rapid liver fibrosis.
31
 K19 is a commonly used marker for the DR but 
not unique as K7 and pan-keratin (Kpan) have similarly been reported as markers delineating the 
same intrahepatic injury response.
32, 33
 Although a number of immunohistochemistry markers of the 
DR are available, the role of the DR and HPC proliferation in post-LT liver injury characterized by 
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rapid fibrosis does require further study. In particular, it is not known whether the complex 
relationships between the DR, HPC proliferation, fibrosis and inflammation seen in non-transplant 
HCV-associated liver injury are recapitulated in the post-LT setting. This is an important question 
to answer in order to better understand the pathogenesis of recurrent HCV and to develop predictive 
markers of aggressive recurrence. 
 
To examine co-regulation of DR, HPC and liver injury responses in recurrent HCV post-LT, we 
studied two distinct LT cohorts. The initial large characterization cohort was used to assess the 
relationships between the DR, replicative arrest, steatosis and fibrosis in livers with HCV 
recurrence post-LT in comparison to donor livers, which served as normal controls. The 
independent second cohort was used to confirm the DR-associated findings of the initial 
characterization cohort and to extend them by also comparing the DR, inflammation and fibrosis in 
the post- versus pre-LT HCV-associated liver injury. 
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MATERIALS AND METHODS 
 
1. Patient Cohorts 
Retrospective studies were conducted in Australia at the Australian National Liver Transplantation 
Unit located at Royal Prince Alfred Hospital in Sydney, New South Wales, and Fremantle Hospital 
in Fremantle, Western Australia. The Sydney cohort comprised 194 liver biopsies obtained from 
105 post-LT patients and 15 biopsies from donor livers prepared for LT were used as normal 
controls. Liver biopsies with co-existing pathology at the time of biopsy other than recurrent HCV 
(such as acute or chronic rejection, bile duct obstruction, bile leak, cholangitis, significant hepatic 
artery thrombosis or stenosis, reperfusion injury, cytomegalovirus infection) were excluded. In the 
second cohort, liver biopsies were available from 37 patients with HCV infection pre- and post-LT, 
sourced from Loma Linda Medical Centre, USA. The Loma Linda cohort was independently 
analyzed to test the robustness of our primary findings.  
 
All necessary ethics approvals for this study were obtained from the Royal Prince Alfred Hospital 
and the University of Sydney, Fremantle Hospital in Fremantle, Western Australia and Loma Linda 
Medical Centre, Los Angeles, USA. 
 
2. Immunohistochemistry  
Immunohistochemistry was performed on formalin-fixed, paraffin-embedded liver biopsies using 
the following primary antibodies: K7 (ductular epithelium and HPC) (1:100, monoclonal mouse 
anti-human, Clone OV-TL 12/30, Dako), α-smooth muscle actin (α-SMA, activated HSCs) (1:100, 
monoclonal FITC-conjugated mouse antibody, Clone 1A4, Sigma-Aldrich), p21
waf1
 (replicative 
arrest marker) (1:50, monoclonal mouse anti-human, Clone EA10, Calbiochem), Ki-67 (cell 
proliferation marker) (1:50, monoclonal mouse anti-human, Clone MIB-1, Dako), Kpan (ductular 
epithelium and HPC) (1:100, polyclonal rabbit anti-panK, Z0622, Dako), and CD45 (leukocyte 
common antigen) (1:100, monoclonal mouse anti-human, Clone 2B11+PD7/26, Dako). The DR and 
HPCs were identified by K7 staining in the Sydney cohort, Kpan staining in the Loma Linda cohort 
and results were confirmed by K19 staining (1:100, monoclonal mouse anti-human, Clone 
RCK108, Dako) in both cohorts. As already discussed, K7, Kpan and K19 all delineate the same 
intrahepatic DR.
17, 32, 33
 The secondary antibodies used were polyclonal rabbit anti-mouse 
immunoglobulins/horseradish peroxidase (HRP) (1:100, Dako) and polyclonal goat anti-rabbit 
immunoglobulins/HRP (1:100, Dako). The primary antibodies were detected using the NovaRED 
peroxidase substrate kit (Vector Laboratories) for the Sydney cohort and VECTASTAIN ABC kit 
(Vector Laboratories) for the Loma Linda cohort. Sirius red staining was performed by incubating 
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liver sections in 0.1% Sirius Red (Direct Red 80, Sigma-Aldrich) and 0.1% Fast Green (Fast Green 
FCF, Sigma-Aldrich) in picric acid solution (Sigma-Aldrich) for 30 minutes. Sections were 
mounted using either Eukitt (Grale Scientific) or VectaMount (Vector Laboratories) mounting 
medium. 
 
3. Quantification and image analysis 
Scanning of tissue sections and image analyses were performed using the Dako Automated Cellular 
Imaging System® III (Sydney cohort), and the Aperio ScanScope whole slide scanning system and 
ImageScope software (Loma Linda cohort), using algorithm-based positive pixel count per area. 
Further, both the Sydney and Loma Linda cohort were quantitated by experienced liver pathologists 
and hepatologists for the extent of the DR as well as quantitation of the HPC response in at least 
three random high power fields per section. As previously described, HPCs were quantitated by 
counting small, immunoreactive cells in the periportal area and expressing them as the number per 
portal tract.
34
  Hepatocyte proliferation and replicative arrest were assessed by counting Ki-67-
positive and p21-positive hepatocyte nuclei, respectively, in ten random lobular fields at 400X 
magnification, and expressing this as a percentage of total hepatocyte nuclei to correct for cellular 
enlargement caused by steatosis. The replicative arrest ratio was determined by calculating the ratio 




4. Histopathological analysis 
Sections were analyzed by experienced liver pathologists who were blinded to the clinical data and 
laboratory parameters. Scheuer's scoring system was used in the initial cohort and this consists of 
necroinflammatory activity assessment in the portal and lobular areas (0-4) and fibrosis staging (0-
4).
35
  Steatosis was graded as 0 (<5% hepatocytes affected), 1 (5-29% of hepatocytes affected), 2 
(30-70% of hepatocytes affected), or 3 (>70% of hepatocytes affected).
13
 The Loma Linda cohort 
used Ishak's scoring system of fibrosis. 
 
5. Immunofluorescence and confocal microscopy 
Immunofluorescence was performed on frozen liver sections fixed with acetone/methanol 50:50 
using the following primary antibodies: α-SMA (1:100, monoclonal Cy3-conjugated mouse 
antibody, Clone 1A4, Sigma-Aldrich), K7 (1:50, monoclonal FITC-conjugated mouse anti-human, 
Clone LPK5, abcam) and Kpan (1:50, polyclonal rabbit anti-panK, Dako). The secondary 
fluorophores used were Alexa Fluor® 488-labeled anti-fluorescein/Oregon Green® goat IgG 
antibody and Alexa Fluor® 647 goat anti-rabbit IgG (1:200, Invitrogen). DAPI (4',6-diamidino-2-
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phenylindole) (Molecular Probes®, Invitrogen) was used to identify nuclei and ProLong® Gold 
antifade reagent (Molecular Probes®, Invitrogen) was used for mounting. 
 
Confocal microscopy was performed using Leica TCS SP5 instrument (Leica Microsystems). The 
laser excitation lines used were 405, 488, 561 and 633 nm. The objective lens utilized was 63X with 
water as the immersion medium. The confocal images were acquired using sequential scanning and 
between lines mode to avoid cross-talk or bleed-through between fluorophores. Z-stacks obtained 
from optical slices of the 30 µm frozen section liver specimens were reconstructed and analyzed 
using Volocity® 3D Image Analysis Software 5.1 (Perkin Elmer). 
 
6. Statistical analysis 
Statistical analyses were performed using SPSS17.0 for Windows (Chicago, USA). Central 
tendency was expressed as median and range. Continuous variables were compared using Mann-
Whitney-U test and categorical variables were compared using Chi-square or Fisher’s exact test as 
appropriate. Spearman method was used for correlation analysis. A p-value <0.05 was considered 
significant.  
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Patient populations and description of the ductular reaction 
Table 1 shows the patients’ gender, age and liver fibrosis stages in both cohorts. In the Sydney 
cohort there were 194 biopsies taken and HCV genotype (G) was documented as G1 38.1%, G2 
1%, G3 23.8%, G4 10.5%, G6 1%, and unknown 25.7%. The distribution of steatosis in this cohort 
was grade 0 in 54.1%, grade 1 in 27.8%, grade 2 in 9.3% and grade 3 in 8.8% of specimens. Three 
patients had cholestatic hepatitis C (Table 2) and these patients had a higher median viral load 
compared to non-cholestatic patients (8.7x10^7 IU/ml vs. 2.84x10^6, p<0.005).  The DR in the liver 
with cholestatic hepatitis C seemed to be more extensive than in the liver with non-cholestatic 
hepatitis C (supplementary Table 4), however given the small number of specimens with cholestatic 
hepatitis C, these did not influence the overall final correlation results (supplementary Figure 7 and 
Table 5) and a subanalysis was unattainable. The DR appeared mainly in the periphery of portal 
tracts as irregular strings of proliferating biliary epithelium with seemingly isolated single cells in 
adjacent areas, which are labeled HPCs (Figure 1A and B). The morphology of the DR was 
consistent with previously described results in the non-LT setting, independent of the antibody used 
for quantitation.
13, 33, 34





Figure 2 shows representative changes in the immunohistochemical markers used for assessment of 
the DR and HPCs (K7), activated HSCs (α-SMA), hepatocyte replicative arrest (p21) and 
hepatocyte proliferation (Ki-67) for donor liver representing non-injured tissue, and changes seen in 
progressive fibrosis following HCV recurrence in the liver allograft (F0-F4). Progressive fibrosis 
was assessed using α-SMA staining (Figure 2) and collagen staining (Sirius red, figure not shown). 
Quantitative data for these parameters are shown in Figure 3.  There was no significant difference 
between the DR in donor livers and non-fibrotic F0 livers with HCV recurrence post-LT (Figure 
3A, p=0.063). However, as fibrosis progressed, the DR increased significantly in both F1-2 and 
advanced F3-4 fibrosis, being more pronounced than observed in donor tissue and F0 tissue. 
Additionally, there was a progressive increase in the extent of the DR with progressive fibrosis, 
such that there was a significant difference between F1-2 and F3-4 fibrosis (Figure 3A, p<0.001). 
Importantly, α-SMA expression paralleled the development of the DR with each stage of fibrosis 
(Figure 3C compared to 3A). The DR in F0 fibrosis was not significantly different to donor. On the 
other hand, in F0 fibrosis the number of activated HSCs had already increased significantly in livers 
with HCV recurrence post-LT compared to donor livers (Figure 3C). The number of activated 
HSCs continued to increase with worsening liver fibrosis, especially in the advanced stages. 
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Assessment of both hepatocyte replicative arrest and proliferation showed that these did differ to 
both the DR and α-SMA expression with each stage of fibrosis (Figure 3E and F). There was a clear 
early increase in both p21 and Ki-67 staining in HCV recurrence without fibrosis (F0), however 
there were no further significant changes through to advanced fibrosis. This was reflected in the 
ratio of p21/Ki-67 expression, which was significantly greater at F0 compared to control (p=0.012). 
Although p21 and Ki-67 expression peaked in mild fibrosis and decreased in moderate-advanced 
fibrosis, the differences were not significant. Steatosis is known to be a co-factor in HCV-
associated liver injury.
13, 36-42
 However, the degree of liver steatosis in the post-LT setting did not 
correlate with the DR (Table 3) or fibrosis in liver with HCV recurrence post-LT (data not shown). 
 
The HPC response was similar to the development of the DR and α-SMA expression accompanying 
progressive fibrosis (Figure 3B). Further, the DR correlated positively with the number of HPCs 
(Figure 1C). An extensive correlative analysis showed that not only did the DR significantly 
correlate with fibrosis (Table 3, rs=0.529, p<0.001), but it also significantly correlated with 
Scheuer's portal necroinflammatory activity (rs=0.400,  p<0.001). However, the DR did not correlate 
with serum HCV RNA levels at the time of liver biopsy, lobular inflammatory activity, or p21 
expression. Further, the DR did correlate with Ki-67 expression (rs=0.295, p<0.001). Importantly, 
as the p21/Ki-67 ratio peaked with early injury, this suggests that hepatocyte replicative arrest 
preceded hepatocyte replication. Additional variables that significantly correlated with the DR 
included total Scheuer score, aspartate aminotransferase (AST), white cell count, platelet count and 
prothrombin time (Table 3). 
 
Confirmation of findings in a separate cohort 
The extent of the DR and numbers of HPC were evaluated in the Loma Linda cohort using Kpan as 
a marker of ductular epithelium and HPC. Representative photomicrographs of K7, Kpan and K19 
staining in F0, F2 and F4 fibrosis in post-LT patients illustrate that the DR/HPC response increased 
in proportion to the degree of fibrosis, irrespective of the DR/HPC marker used (Figure 4A). This is 
consistent with published studies.
17, 32, 33
 Confocal analysis of K7 and Kpan immunofluorescent 
staining confirmed that these two markers identified the same cell populations (Figure 4B). 
Quantitation of Kpan-positive cells showed a strong significant correlation between the extent of 
the DR and numbers of HPC (Figure 5A and B, p=0.0001) and confirmed that the DR directly 
correlates with the fibrosis severity in both pre- as well as post-LT HCV-infected livers (Figure 5C 
and D). Further, in the Loma Linda cohort it was also demonstrated in both patient groups that the 
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DR correlated to hepatic inflammation, as judged by quantitation of cells positive for the leukocyte 
common antigen CD45 and represented by Ishak's inflammation score (Figure 5E and F).  
 
 
Confocal immunofluorescence characterization of the ductular reaction 
Confocal analysis of K7-positive DR structures and α-SMA-expressing HSCs in post-LT liver 
sections showed that the DR is mostly seen in periportal regions, which is also the location of most 
activated, fibrosis-driving HSCs in HCV-infected livers. Importantly, these cell populations were 
always in close proximity. However, despite their significant correlation, K7- and α-SMA-positive 
structures never co-localized within the same cell (Figure 6A-C).  
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Proliferation of HPCs and the DR are encountered in most liver diseases associated with 
hepatocellular necrosis.
22, 43
 This alternative regeneration pathway becomes activated when the 
replicative capacity of mature hepatocytes is compromised.
22, 44, 45
 HPCs then differentiate towards 
either cholangiocytes or hepatocytes to repair and compensate for the anatomical and functional 
loss of injured cells. The degree of HPC activation increases in parallel with the severity of fibrosis 
and liver injury.
13, 15, 21
 To date, there has been little information provided on the roles of the DR, 
noted to comprise a population of HPCs, and inflammation in liver allograft injury and fibrosis 
associated with HCV recurrence post-LT. Our results confirm that there is a DR and HPC response 
associated with progressive fibrosis seen with HCV recurrence post-LT. This appears to be 
analogous to, but greatly accelerated compared to the pre-LT setting. The studies in both cohorts 
were undertaken contemporaneously and importantly yielded the same results, demonstrating that 
our findings were significant independent of the antibodies and methodologies used for analyses. In 
addition, we have shown replicative arrest precedes hepatocyte proliferation in early stage injury. 
 
The DR was not evident in donor livers or in non-diseased livers and was only activated in response 
to liver injury, which is consistent with observations in pre-LT patients with HCV infection.
13, 15
 In 
the Sydney cohort, we demonstrated in post-LT livers that the DR only correlated significantly with 
portal but not lobular necroinflammatory activity. The Loma Linda cohort confirmed and extended 
these findings by demonstrating a positive correlation between the DR, fibrosis and inflammation in 
both pre- and post-LT patients. Since HCV-induced hepatic fibrosis typically occurs in the 
periportal area, this further supports the hypothesis that portal inflammation is likely to be the 
common stimulus driving HPC expansion, the DR, HSC activation and consequently fibrogenesis. 
The DR in the liver with cholestatic hepatitis C seemed to be more exaggerated than in the liver 
with non-cholestatic hepatitis C. However meaningful subanalysis was unattainable given the very 
small number of specimens with cholestatic hepatitis C, and further study is warranted on this 
special population. 
 
It has been suggested that HPC activation can be triggered by impaired hepatocyte replication.
22, 45
 
Previous studies have reported a correlation between hepatocyte replicative arrest and HPC/DR 
proliferation in the non-LT setting with HCV-related liver injury
13, 34
, which is associated with p21-
regulated hepatocyte G1 arrest.
46
 In post-LT HCV-infected livers, increased hepatocyte replicative 
arrest and Ki-67-positivity were seen in liver without significant fibrosis (F0) and both remained 
significantly increased in early and advanced stage fibrosis. We can postulate that this reflects 
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increased numbers of hepatocytes in G1-arrest in an initial attempt to compensate for hepatocytes 
loss, which then in turn leads to HPC/DR activation. Importantly, there was no significant 
difference in either p21 or Ki-67 expression between fibrosis stages suggesting that this is a 
sustained response to HCV-associated liver injury following LT. The reduction in both hepatocyte 
replicative arrest and proliferation markers in the advanced stages of liver fibrosis, though not 
statistically significant, might reflects an overall loss in the hepatocytes mass accompanying the 
development of cirrhosis. 
 
Damage to hepatocytes may also contribute to the activation of HSCs.
47
 In livers with HCV 
recurrence post-LT, there was a significant increase in activated HSCs compared to donor livers. 
This finding was associated with the highest hepatocyte replicative arrest to proliferation ratio. Our 
results are consistent with previously published data, which demonstrated that HSC activation may 
start early in recurrent HCV disease post-LT, which can predict rapid disease progression.
31, 48, 49
 As 
expected, the numbers of activated HSCs continued to increase in the post-LT biopsies with 
progressive fibrosis, confirming their pivotal role in recurrent HCV-associated liver injury. 
 
Given its proximity to and positive correlations with fibrosis, the DR has been suggested to contain 
HSCs and mesenchymal cell populations.
31, 43, 50, 51
 Detailed analysis using high power confocal 
microscopy and 3D image analyses, however, showed that markers for DR cells and activated 
HSCs never co-localized. These findings are consistent with the observations of Ruddell et al., 
which also demonstrated that HPCs and HSCs are closely associated but remain as distinct cells 




Inflammation and fibrogenesis have previously been shown to be co-regulated within the liver.
13, 17, 
34, 52, 53
 It is likely that a common stimulus, related to HCV infection and inflammation, triggers the 
DR and activates HSC, with subsequent auto- and paracrine processes between the cells involved. It 
has been suggested that fibrosis follows HPC responses.
13, 17
 Clouston, et al. observed the presence 
of a fine DR in some patients without fibrosis.
13
 Our data showed the DR in non-fibrotic livers with 
HCV recurrence post-LT. Further, we have shown that initiation of HPC proliferation stimulates 
activation of HSCs in a mouse model of chronic liver injury induced by a choline-deficient, 
ethionine-supplemented diet.
17, 52
 Moreover, inhibition of the HPC response to liver injury prevents 
liver fibrosis and cancer development in animal models 
54
, whilst augmentation of the HPC 
response results in more severe liver fibrosis.
52
 Our observation of the early detection of activated 
HSCs prior to the appearance of fibrosis supports the growing body of evidence that early activation 
precedes fibrosis and occurs contemporaneously with HPC activation.
48, 49
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Due to the cross-sectional nature of our study, it remains unclear as to whether the early activation 
of HSCs might be predictive of earlier and progressive liver fibrosis with worse outcome. 
Longitudinal studies in the same patients would be required to confirm this as a marker to identify 
individuals with HCV recurrence post-LT who may benefit from close monitoring and early 
antiviral therapy. 
 
In summary, our data indicate that post-LT recurrent HCV-induced liver injury contributes to 
hepatocellular damage and impaired regeneration with subsequent HPC proliferation, DR formation 
and HSC activation. The exact mechanisms and sequences of these injury responses are unclear. 
However, the current and previous studies indicate that hepatic inflammation occurring in HCV-
associated liver injury, either pre- or post-LT, would appear to drive both fibrosis and HPC 
proliferation and the DR. Our study has confirmed and extended previous observations in a variety 
of pre-LT chronic liver diseases linking inflammation, HPC proliferation, the DR and fibrogenesis. 
We have now shown a similar response with post-LT recurrent HCV injury. It is likely that future 
therapies for chronic liver disease, which target the mechanisms underlying the inflammation-
HPC/DR-fibrogenesis association, are likely to be applicable in both pre- and post-LT HCV-
associated liver disease.  
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Table 1. Patient age, sex and fibrosis stages for both cohorts and Ishak score for the Loma Linda 
cohort. 
 Sydney Cohort Loma Linda Cohort 
 Number % LT  Non-LT 
Total 
Male patients 
Age ± SEM (years) 
105 
86 






15 (78.9%)  
66.8 ± 0.84 
18 (100%) 
12 (66.7%) 
67.2 ± 1.08 
Fibrosis stage 
Number of liver 
biopsy %   
F0 65 33.5% 4 (21.1%) 1 (5.6%) 
F1 56 28.9% 4 (21.1%) 5 (27.8%) 
F2 42 21.6% 4 (21.1%) 3 (16.7%) 
F3 20 10.3% 3 (15.8%) 4 (22.2%) 
F4 11 5.7% 4 (21.1%) 5 (27.8%) 
Total Ishak score     
0 - - 0 (0%) 1 (5.6%) 
1 - 2 - - 3 (15.8%) 6 (33.3%) 
3 - 4 - - 5 (26.3%) 6 (33.3%) 
5 - 6 - - 7 (36.8%) 4 (22.2%) 













Patients (n, male) 3 (1) 102 (85) 105 (86)  
Liver biopsy (n) 5 189 194  
HCV RNA 
(median, IU/ml) 
8.7x10^7 2.84x10^6 2.93x10^6 
 
p<0.005 
(cholestatic  vs  non-
cholestatic hepatitis C) 
Fibrosis stage     
F0 2 63 65  
F1 1 55 56  
F2 1 41 42  
F3 0 20 20  
F4 1 10 11  
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Correlation analysis was performed using Spearman method. 
*Scheuer's score components. 
Variables Ductular reaction p-value 
Lobular activity* 0.120 p=0.098 
Portal activity* 0.400 p<0.001 
Fibrosis stage* 0.529 p<0.001 
Total Scheuer score 0.494 p<0.001 
α-SMA 0.446 p<0.001 
Steatosis grade 0.090 p=0.214 
Replicative arrest (p21 +) 0.107 p=0.202 
Proliferative index (Ki-67 +) 0.295 p<0.001 
Replicative arrest ratio -0.088 p=0.334 
HCV RNA 0.001 p=0.992 
Bilirubin 0.034 p=0.636 
ALT -0.050 p=0.496 
AST 0.167 p=0.025 
ALP -0.008 p=0.916 
GGT 0.003 p=0.964 
Albumin -0.083 p=0.264 
Hemoglobin -0.092 p=0.207 
White cell -0.217 p=0.003 
Platelet -0.160 p=0.027 
Prothrombin time 0.208 p=0.020 
Serum creatinine -0.031 p=0.674 
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Figure 1. The ductular reaction in liver with HCV recurrence post-liver transplantation. 
The DR, identified by keratin-7 (K7, A) and pan-keratin (Kpan, B), is seen in the periportal area 
and can be differentiated from bile ducts (bold arrows) by its morphology as irregular strings with 
poorly defined lumen or single HPCs (thin arrows). There was significant correlation between the 
extent of the ductular reaction and number of HPCs (p<0.001). 
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Figure 2. Expression of DR, fibrosis, replicative arrest and proliferative markers with 
progressive post-transplant HCV-associated fibrosis. 
Photomicrographs of representative immunohistochemical panels of the DR (keratin-7, K7), 
activated HSCs (α-SMA), hepatocyte replicative arrest (p21) and hepatocyte proliferation (Ki-67) 
of donor liver tissue (D) and all stages of fibrosis (F0-F4) from individuals with HCV recurrence 
post-LT. 
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Figure 3. Quantitation of markers of the DR, fibrosis, replicative arrest and proliferation 
with progressive fibrosis in HCV recurrence post-LT. 
Quantitative data for the DR (keratin-7, K7, A), HPCs (K7, B), activated HSCs (α-SMA, C), 
collagen deposition (Sirius red, D), replicative arrest (p21, E) and hepatocyte proliferation (Ki-67, 
F) in donor liver tissue and all stages of fibrosis (F0-F4) from individuals with HCV recurrence 
post-LT biopsies. (Means ± SE. *p<0.05, **p<0.01, ***p<0.001). Biopsy numbers correspond to 
the numbers listed in Table 1. 
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Figure 4.  Cross-validation of DR and HPC responses using different immunomarkers. 
Immunohistochemical staining of the DR and HPCs with keratin-7 (K7), K19 and pan-keratin 
(Kpan) antibodies illustrates consistent detection of the same structures in representative panels of 
F0, F2 and F4 fibrosis, cross-validating findings in two separate cohorts (A). Confocal analysis of 
K7- (green) and Kpan-positive (red) cells confirms co-localization of the antigens in the same cells 
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Figure 5 Quantitation of the DR using pan-keratin in the Loma Linda cohort 
The DR, as assessed by pan-keratin (Kpan) staining quantitation, shows significant correlations 
with HPC numbers (A, B), fibrosis grade (C, D) and hepatic inflammation according to Ishak score 
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Figure 6.  Confocal microscopy of the DR and activated HSCs. 
Confocal analysis of immunofluorescent stainings for keratin-7 (K7, DR and HPCs, green), α-SMA 
(activated HSCs, red) and DAPI (nuclear-stain, blue) demonstrates that the DR (B) and activated 
myofibroblasts (C) are identified in very close proximity in periportal areas. However, despite their 
strong correlation these markers did not co-localize and definitely distinguish distinct cell 
populations (A, merged). 
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Supplementary Table 4. Quantitation of markers of the DR, fibrosis, replicative arrest and 



















































































































































































 Ductular reaction, α-SMA and Sirius red were analyzed by algorithm-based positive pixel count 
per area. HPCs were quantitated by counting small, immunoreactive cells in the periportal area and 
expressing them as the number per portal tract. Hepatocyte proliferation and replicative arrest were 
assessed by counting Ki-67-positive and p21-positive hepatocyte nuclei, respectively, in ten random 
lobular fields at 400X magnification, and expressing this as a percentage of total hepatocyte nuclei. 
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Supplementary Figure 7. The correlation between the ductular reaction and HPC numbers in 
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Supplementary Table 5. Correlations of the DR with histological and clinical variables in the 























Correlation analysis was performed using Spearman method. 
*Scheuer's score components. 
Variables Ductular reaction p-value 
Lobular activity* 0.107 p=0.144 
Portal activity* 0.389 p<0.001 
Fibrosis stage* 0.529 p<0.001 
Total Scheuer score 0.488 p<0.001 
α-SMA 0.440 p<0.001 
Steatosis grade 0.110 p=0.130 
Replicative arrest (p21 +) 0.112 p=0.185 
Proliferative index (Ki-67 +) 0.303 p<0.001 
Replicative arrest ratio -0.090 p=0.327 
HCV RNA -0.004 p=0.967 
Bilirubin 0.004 p=0.952 
ALT -0.069 p=0.346 
AST 0.135 p=0.075 
ALP 0.001 p=0.986 
GGT 0.003 p=0.963 
Albumin -0.064 p=0.394 
Hemoglobin -0.084 p=0.254 
White cell -0.237 p=0.001 
Platelet -0.136 p=0.063 
Prothrombin time 0.194 p=0.034 
Serum creatinine -0.011 p=0.880 
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Figure 1. The ductular reaction in liver with HCV recurrence post-liver transplantation.  
The DR, identified by keratin-7 (K7, A) and pan-keratin (Kpan, B), is seen in the periportal area and can be 
differentiated from bile ducts (bold arrows) by its morphology as irregular strings with poorly defined lumen 
or single HPCs (thin arrows). There was significant correlation between the extent of the ductular reaction 
and number of HPCs (p<0.001).  
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Figure 2. Expression of DR, fibrosis, replicative arrest and proliferative markers with progressive post-
transplant HCV-associated fibrosis.  
Photomicrographs of representative immunohistochemical panels of the DR (keratin-7, K7), activated HSCs 
(α-SMA), hepatocyte replicative arrest (p21) and hepatocyte proliferation (Ki-67) of donor liver tissue (D) 
and all stages of fibrosis (F0-F4) from individuals with HCV recurrence post-LT.  
219x256mm (300 x 300 DPI)  
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Figure 3. Quantitation of markers of the DR, fibrosis, replicative arrest and proliferation with progressive 
fibrosis in HCV recurrence post-LT.  
Quantitative data for the DR (keratin-7, K7, A), HPCs (K7, B), activated HSCs (α-SMA, C), collagen 
deposition (Sirius red, D), replicative arrest (p21, E) and hepatocyte proliferation (Ki-67, F) in donor liver 
tissue and all stages of fibrosis (F0-F4) from individuals with HCV recurrence post-LT biopsies. (Means +/- 
SE. *p<0.05, **p<0.01, ***p<0.001). Biopsy numbers correspond to the numbers listed in Table 1.  
119x130mm (300 x 300 DPI)  
 
 
Page 33 of 37





Figure 4. Cross-validation of DR and HPC responses using different immunomarkers.  
Immunohistochemical staining of the DR and HPCs with keratin-7 (K7), K19 and pan-keratin (Kpan) 
antibodies illustrates consistent detection of the same structures in representative panels of F0, F2 and F4 
fibrosis, cross-validating findings in two separate cohorts (A). Confocal analysis of K7- (green) and Kpan-
positive (red) cells confirms co-localization of the antigens in the same cells (yellow, merged) (B).  
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Figure 5 Quantitation of the DR using pan-keratin in the Loma Linda cohort  
The DR, as assessed by pan-keratin (Kpan) staining quantitation, shows significant correlations with HPC 
numbers (A, B), fibrosis grade (C, D) and hepatic inflammation according to Ishak score (E, F) in both pre-
LT as well as post-LT setting. Data are represented as means +/- SE (*p<0.05, **p<0.01).  
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Figure 6. Confocal microscopy of the DR and activated HSCs.  
Confocal analysis of immunofluorescent stainings for keratin-7 (K7, DR and HPCs, green), α-SMA (activated 
HSCs, red) and DAPI (nuclear-stain, blue) demonstrates that the DR (B) and activated myofibroblasts (C) 
are identified in very close proximity in periportal areas. However, despite their strong correlation these 
markers did not co-localize and definitely distinguish distinct cell populations (A, merged).  
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Supplementary Figure 7. The correlation between the ductular reaction and HPC numbers in liver with non-
cholestatic HCV recurrence post-LT (p<0.001).  
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